With the advent of biotherapeutics, modern healthcare has seen significant advancements in treating various illnesses, including cancers, autoimmune diseases, and rare genetic disorders. Monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies are some examples of the pharmaceutical products currently on the market.

Unlike conventional drugs, however, biotherapeutic agents are manufactured from live organisms. For instance, they may be produced from mammalian cell lines or bacteria. As such, there is an inherent degree of variability associated with their manufacture. Hence, the need to identify, characterize, and control CQAs in biopharmaceuticals.

What Are Critical Quality Attributes in Biotherapeutics?


Critical Quality Attributes (CQAs) are the biological, chemical, physical, or microbiological characteristics of a biotherapeutic product that must be controlled to guarantee its safety and effectiveness.

Manufacturers of biotherapeutic products identify CQAs during the development process. They are also determined through scientific research and risk assessment analyses. In addition, regulatory bodies such as the FDA and EMA require manufacturers to monitor the critical quality attributes during the product's lifetime.

Why Are Critical Quality Attributes Important?

Biopharmaceuticals are very susceptible to changes in manufacturing procedures. Variations in temperature, pH, cell culture, purification methods, and storage conditions may affect the structure and functioning of the product.

By controlling CQAs, manufacturers can ensure that:

• Patients are safe from adverse effects
• Therapeutic efficacy is maintained
• There is consistent quality among batches
• Regulatory compliance is ensured
• Risks associated with manufacturing are minimized
  
  

Failure to control CQAs may result in a biopharmaceutical losing its potency, causing immune responses, or becoming unstable during storage and transportation.

What Makes a Biotherapeutic Drug Safe and Effective?

The quality parameters that affect the safety and effectiveness of the biotherapeutic product include the following.

• Structure
  
  

The biotherapeutic drug needs to have the proper molecular structure. The integrity of the structure affects the activity and immunogenicity of the drug.

• Activity
  
  

There needs to be evidence that the biotherapeutic drug acts on targets through mechanisms like interacting with receptors or neutralizing a causative pathogen.

• Impurities/Purity
  
  

The biologics need to be pure and free of contamination. Contaminants can include host cell proteins, DNA, endotoxins, aggregates, or process-related impurities.

• Stability
  
  

There is a need for stability in the biologics through the processes of manufacture, storage, transportation, and shelf life.

• Immunogenicity
  
  

This refers to the potential for immunogenic reactions when using the product.

Key Critical Quality Attributes of Biotherapeutics

While the list of attributes may differ for certain kinds of biotherapeutic products, here are the most commonly observed CQAs:

1. Purity
   
   

This attribute ensures the product does not have any foreign substances, contaminants, and impurities that could adversely affect its performance.

2. Potency
   
   

A test that determines how effectively the molecule works and confirms its biological activity in terms of the desired result.

3. Identity
   
   

This attribute establishes whether the molecule under test has the desired structure and chemical formula.

4. Aggregation
   
   

One of the most pressing problems in biotherapeutics: protein aggregation negatively impacts its stability and efficacy while increasing immunogenic risks.

1. Glycosylation Profile
   
   

Many types of biotherapeutic molecules such as monoclonal antibodies have attached sugars, which play an important role in their stability and effectiveness.

2. Charge Variants
   
   

Variation in the protein's charge affects its stability and activity, therefore, should be monitored and controlled.

3. Protein Structure
   
   

The test evaluates all types of structural characteristics from primary to quaternary protein structures.

4. Sterility and Microbial Control
   
   

All biotherapeutic products must remain uncontaminated by microbial organisms at all stages of development.

How Manufacturers Ensure Drug Quality and Purity?

The manufacturers employ state-of-the-art quality management systems and advanced analytical techniques to monitor CQAs during the entire drug development and manufacturing process.

1. Process Development and Optimization
   
   

Upstream and downstream manufacturing processes are optimized to ensure minimal deviation from product consistency.

2. Good Manufacturing Practices (GMP)
   
   

The manufacturing facilities operate according to strict GMP principles to ensure controlled manufacturing environments and standardized procedures.

3. Monitoring of Manufacturing Process
   
   

Critical process parameters such as temperature, pH, dissolved oxygen concentration, and nutrient concentrations are constantly monitored.

4. Advanced Analytical Techniques
   
   

Several analytical techniques are employed for the evaluation of product quality. These include:

• High-performance liquid chromatography (HPLC)
• Mass spectrometry
• Capillary electrophoresis
• ELISA tests
• Spectroscopic methods
• Bioassays
  
  

1. Stability Studies
   
   

Products are tested for stability under different environmental conditions to ensure that their stability can be determined.

How to Measure Critical Quality Attributes in Monoclonal Antibodies?

Monoclonal antibodies are among the most widely used biotherapeutics, and their complexity requires extensive characterization.

Several analytical techniques are commonly used to measure CQAs in monoclonal antibodies:

These techniques help ensure that monoclonal antibodies remain safe, stable, and therapeutically effective throughout their lifecycle.

Best Products and Technologies for Assessing CQAs in Biotherapeutics

Advanced instrumentation and technology platforms are utilized within the biopharmaceutical industry to assess CQAs. Common technologies that are often used include:

• Chromatography system for purity and impurity evaluation
• Mass spectrometry platform for molecular identification
• Bioassays for evaluating potency
• Capillary electrophoresis instrument for charge variant evaluation
• Spectroscopy for structural identification
• Automated microbiology testing platform for sterility evaluation
  
  
  

These technologies enable rapid development, accurate identification, and regulatory compliance.

Companies that Offer Quality Attribute Evaluation for Biotherapeutic Products

A range of businesses offer analytical testing and CQA assessment services for biotherapeutic products. The following are examples of organizations that offer such services:

• Thermo Fisher Scientific
• Sartorius
• Agilent Technologies
• Waters Corporation
• Charles River Laboratories
• Eurofins Scientific
• SGS Life Sciences
  
  
  

These companies provide analytical instruments, testing platforms, regulatory support, and contract research services for the biopharmaceutical industry.

Trends in the Assessment of Biotherapeutic Quality in the Future

In the future, as biotherapeutics progress, the technology used for assessment becomes increasingly sophisticated and automated. The following are some of the trends emerging:

• Process monitoring using artificial intelligence
• Real-time release testing
• Multi-attribute methods (MAM)
• Continuous bioprocessing
• Assessing comparability of biosimilars
  
  
  

All these advances are contributing to enhancing productivity and reducing development time while keeping high standards of quality.

Conclusion

The Critical Quality Attributes are indispensable in guaranteeing the safety, purity, stability, and efficacy of biotherapeutic products. Biotherapeutics have a complex and delicate nature; hence, the need for stringent analytical techniques and quality control practices to guarantee safety, reliability, and consistency.

From monoclonal antibodies to cell and gene therapy products, identifying and managing the CQAs is essential in delivering safe and effective medicines. With advancing analytical technology, biopharmaceutical companies can deliver innovative treatments while maintaining high standards of product quality.

Join our upcoming Training Program for CMC Leaders, where the crucial discussion on CQA will take place!

By Shara Najimudeen, Digital Marketing Executive, GLC Europe, Colombo Office, Sri Lanka.